David P Dearnaley

发表

Variability of bladder filling in patients receiving radical radiotherapy to the prostate.

Simon Hooper, D. Dearnaley, R. Huddart, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise.

Steve Webb, Philip M Evans, Mike Partridge, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Multiple loci with different cancer specificities within the 8q24 gene desert.

John L Hopper, Honglin Song, Thibaud Koessler, 2008, Journal of the National Cancer Institute.

Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).

Steve Webb, Stefano Gianolini, S. Webb, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Technological advances in radiotherapy for the treatment of localised prostate cancer.

Alan Horwich, D. Dearnaley, A. Horwich, 2005, European journal of cancer.

Quality of treatment plans and accuracy of in vivo portal dosimetry in hybrid intensity-modulated radiation therapy and volumetric modulated arc therapy for prostate cancer.

James L Bedford, Gregory Smyth, D. Dearnaley, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Stereotactic body radiotherapy for oligometastases.

Merina Ahmed, R. Eeles, D. Dearnaley, 2013, The Lancet. Oncology.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

Peter Kraft, Anssi Auvinen, Henrik Gronberg, 2013, Nature Genetics.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397)

Steve Webb, Mike Partridge, Florian Buettner, 2009, Physics in medicine and biology.

A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy.

John Staffurth, D. Dearnaley, A. Norman, 2006, International journal of radiation oncology, biology, physics.

The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial.

Steve Webb, Mike Partridge, Florian Buettner, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Noel W Clarke, Gerhardt Attard, Nicholas D James, 2014, European urology.

A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.

D. Dearnaley, C. Parker, V. Morgan, 2009, European urology.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Suzanne Chambers, Peter Kraft, Anssi Auvinen, 2013, Human molecular genetics.

Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.

Steve Webb, Philip M Evans, Mike Partridge, 2010, International journal of radiation oncology, biology, physics.

A comparison of forward and inverse planned conformal, multi segment and intensity modulated radiotherapy for the treatment of prostate and pelvic nodes.

Jaap Vaarkamp, D. Dearnaley, E. Adams, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer

Alan Horwich, D. Dearnaley, A. Horwich, 2007, BJU international.

A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1

Alison M Dunning, Ángel Carracedo, Emma Hall, 2014, Nature Genetics.

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study

Suzanne Chambers, Peter Kraft, Henrik Gronberg, 2011, Nature Genetics.

Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement.

Steve Webb, Jaap Vaarkamp, Vivian P Cosgrove, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.